Literature DB >> 19603523

Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.

Kylie L Gorringe1, Manasa Ramakrishna, Louise H Williams, Anita Sridhar, Samantha E Boyle, Jennifer L Bearfoot, Jason Li, Michael S Anglesio, Ian G Campbell.   

Abstract

Ovarian cancer is characterized by complex genetic alterations, including copy number loss and copy number-neutral loss of heterozygosity (LOH). These alterations are assumed to represent the "second hit" of the underlying tumor suppressor gene (TSG), however, relative to the number of LOH hotspots reported, few ovarian TSGs have been identified. We conducted a high-resolution LOH analysis using SNP arrays (500K and SNP6.0) of 106 primary ovarian tumors of various histological subtypes together with matching normal DNA. LOH was detected in at least 35% of samples on chromosomes 17, 19p, 22q, Xp, 13q, 8p, 6q, 4q, 5q, 1p, 16q, and 9q with a median minimal region of overlap of only 300 kb. Subtype-specific differences in LOH frequency were noted, particularly for mucinous cases. We also identified 192 somatic homozygous deletions (HDs). Recurrent HDs targeted known TSGs such as CDKN2A (eight samples), RB1 (five samples), and PTEN (three samples). Additional recurrent HDs targeted 16 candidate TSGs near minimal regions of LOH on chromosomes 17, 13, 8p, 5q, and X. Given the importance of HDs in inactivating known genes, these candidates are highly likely to be ovarian TSGs. Our data suggest that the poor success of previous LOH studies was due to the inability of previous technology to resolve complex genomic alterations and distinguish true LOH from allelic imbalance. This study shows that recurrent regions of LOH and HD frequently align with known TSGs suggesting that LOH analysis remains a valid approach to discovering new candidates. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19603523     DOI: 10.1002/gcc.20694

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  25 in total

1.  Silence of HIN-1 expression through methylation of its gene promoter in gastric cancer.

Authors:  Yan Gong; Ming-Zhou Guo; Zhi-Jia Ye; Xiu-Li Zhang; Yong-Liang Zhao; Yun-Sheng Yang
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer.

Authors:  Aung Ko Win; Sean P Cleary; James G Dowty; John A Baron; Joanne P Young; Daniel D Buchanan; Melissa C Southey; Terrilea Burnett; Patrick S Parfrey; Roger C Green; Loïc Le Marchand; Polly A Newcomb; Robert W Haile; Noralane M Lindor; John L Hopper; Steven Gallinger; Mark A Jenkins
Journal:  Int J Cancer       Date:  2011-04-08       Impact factor: 7.396

3.  Two types of primary mucinous ovarian tumors can be distinguished based on their origin.

Authors:  Michiel Simons; Femke Simmer; Johan Bulten; Marjolijn J Ligtenberg; Harry Hollema; Shannon van Vliet; Richarda M de Voer; Eveline J Kamping; Dirk F van Essen; Bauke Ylstra; Lauren E Schwartz; Yihong Wang; Leon F Massuger; Iris D Nagtegaal; Robert J Kurman
Journal:  Mod Pathol       Date:  2019-11-06       Impact factor: 7.842

4.  Mutational inactivation of STAG2 causes aneuploidy in human cancer.

Authors:  David A Solomon; Taeyeon Kim; Laura A Diaz-Martinez; Joshlean Fair; Abdel G Elkahloun; Brent T Harris; Jeffrey A Toretsky; Steven A Rosenberg; Neerav Shukla; Marc Ladanyi; Yardena Samuels; C David James; Hongtao Yu; Jung-Sik Kim; Todd Waldman
Journal:  Science       Date:  2011-08-19       Impact factor: 47.728

5.  Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis.

Authors:  Manasa Ramakrishna; Louise H Williams; Samantha E Boyle; Jennifer L Bearfoot; Anita Sridhar; Terence P Speed; Kylie L Gorringe; Ian G Campbell
Journal:  PLoS One       Date:  2010-04-08       Impact factor: 3.240

6.  Copy number analysis identifies novel interactions between genomic loci in ovarian cancer.

Authors:  Kylie L Gorringe; Joshy George; Michael S Anglesio; Manasa Ramakrishna; Dariush Etemadmoghadam; Prue Cowin; Anita Sridhar; Louise H Williams; Samantha E Boyle; Nozomu Yanaihara; Aikou Okamoto; Mitsuyoshi Urashima; Gordon K Smyth; Ian G Campbell; David D L Bowtell
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

Review 7.  Synthetic lethality and cancer: cohesin and PARP at the replication fork.

Authors:  Nigel J O'Neil; Derek M van Pel; Philip Hieter
Journal:  Trends Genet       Date:  2013-01-18       Impact factor: 11.639

8.  A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions.

Authors:  Wen Xue; Thomas Kitzing; Stephanie Roessler; Johannes Zuber; Alexander Krasnitz; Nikolaus Schultz; Kate Revill; Susann Weissmueller; Amy R Rappaport; Janelle Simon; Jack Zhang; Weijun Luo; James Hicks; Lars Zender; Xin Wei Wang; Scott Powers; Michael Wigler; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-07       Impact factor: 11.205

9.  Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes.

Authors:  David J McBride; Dariush Etemadmoghadam; Susanna L Cooke; Kathryn Alsop; Joshy George; Adam Butler; Juok Cho; Danushka Galappaththige; Chris Greenman; Karen D Howarth; King W Lau; Charlotte K Ng; Keiran Raine; Jon Teague; David C Wedge; Australian Ovarian Cancer Study Group; Xavier Caubit; Michael R Stratton; James D Brenton; Peter J Campbell; P Andrew Futreal; David Dl Bowtell
Journal:  J Pathol       Date:  2012-07-02       Impact factor: 7.996

10.  Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease.

Authors:  Ingiridur Skirnisdottir; Markus Mayrhofer; Maria Rydåker; Helena Akerud; Anders Isaksson
Journal:  BMC Cancer       Date:  2012-09-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.